1. Wierzbinski KR, Szymanski T, Rozwadowska N, Rybka JD, Zimna A, Zalewski T, Nowicka-Bauer K, Malcher A, Nowaczyk M, Krupinski M, Fiedorowicz M, Bogorodzki P, Grieb P, Giersig M, Kurpisz MK.Potential use of superparamagnetic iron oxide nanoparticles for in vitro and in vivo bioimaging of human myoblasts. Sci Rep. 2018 Feb 27;8(1):3682. doi: 10.1038/s41598-018-22018-0.
2. Gwizdala A, Rozwadowska N, Kolanowski TJ, Malcher A, Cieplucha A, Perek B, Seniuk W, Straburzynska-Migaj E, Oko-Sarnowska Z, Cholewinski W, Michalak M, Grajek S, Kurpisz M. Safety, feasibility and effectiveness of first in-human administration of muscle-derived stem/progenitor cells modified with connexin-43 gene for treatment of advanced chronic heart failure.Eur J Heart Fail. 2017 Jan;19(1):148-157. doi: 10.1002/ejhf.700.
3. Wiernicki B, Rozwadowska N, Malcher A, Kolanowski T, Zimna A, Rugowska A, Kurpisz M. Human myoblast transplantation in mice infarcted heart alters the expression profile of cardiac genes associated with left ventricle remodeling. Int J Cardiol. 2016 Jan 1;202:710-21. doi: 10.1016/j.ijcard.2015.09.115.
4. Kolanowski TJ, Rozwadowska N, Malcher A, Szymczyk E, Kasprzak JD, Mietkiewski T, Kurpisz M. In vitro and in vivo characteristics of connexin 43-modified human skeletal myoblasts as candidates for prospective stem cell therapy for the failing heart. Int J Cardiol. 2014 Apr 15;173(1):55-64. doi: 10.1016/j.ijcard.2014.02.009